Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019

Hotte, Sébastien J.; Kapoor, Anil; Basappa, Naveen S.; Bjarnason, Georg A.; Canil, Christina; Conter, Henry Jacob; Czaykowski, Piotr; Graham, Jeffrey; Gray, Samantha; Heng, Daniel Yick Chin; Karakiewicz, Pierre I.; Kollmannsberger, Christian; Lalani, Aly-Khan A.; North, Scott; Patenaude, François; Soulières, Denis; Violette, Phillippe; Winquist, Eric; Wood, Lori; Dudani, Shaan; Maloni, Ranjena; Reaume, M. Neil

doi:10.5489/cuaj.6256

Cited by 11 publications

(6 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5][6] The 2019 consensus statement by the Kidney Cancer Research Network of Canada (KCRNC) introduced the role of immunotherapy as first-line systemic therapy for mRCC, either as doublet immunotherapy or in combination with a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), based on phase 3 studies that demonstrated improved survival compared to single-agent VEGFR-TKI (sunitinib). [7][8][9] Subsequently, there have been updates on two of the important previously report-ed phase 3 studies (CheckMate 214 and Keynote-426) that have reinforced prior results. 10,11 In addition, there have been two new phase 3 studies published (CLEAR and CheckMate 9ER) of immunotherapy + VEGFR-TKI also demonstrating survival benefit over VEGFR-TKI alone.…”

Section: Introductionmentioning

confidence: 96%

“…13 The current consensus statement is based on the deliberations and conclusions of key Canadian opinion leaders in the management of advanced renal cell cancer who convened during the 11th Canadian Kidney Cancer Forum, held virtually on October 16, 2020. During that session, the authors reviewed the previous advanced disease management consensus statements, published in 2019, 7 discussed the recent relevant evidence, and reached consensus on the revised statements published below.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

Canil¹,

Kapoor²,

Basappa³

et al. 2021

CUAJ

Self Cite

View full text Add to dashboard Cite

To answer the multiple-choice questions associated with this article, go to: www.cuasection3credits.org/cuajapril2021. This program is an Accredited Self-Assess-ment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by the Canadian Urological Association. Remember to visit MAINPORT (www.mainport.org/mainport/) to record your learning and outcomes. You may claim a maximum of 1 hour of credit.

show abstract

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

Canil¹,

Kapoor²,

Basappa³

et al. 2021

CUAJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…Brain metastases (BM) in metastatic renal cell carcinoma (mRCC) have a reported incidence that ranges between 5% and 25% 1,2 . Until recently, national and international consensus guidelines have not recommended the routine use of intra‐cranial imaging to screen for BM in patients with renal cell carcinoma (RCC) in the absence of symptoms 3–5 . The more recent 2022 European Association of Urology Guidelines on Renal Cell Carcinoma similarly do not recommend routine brain imaging for patients with RCC, but suggest offering brain imaging for patients with mRCC 6 .…”

Section: Introductionmentioning

confidence: 99%

“… 1 , 2 Until recently, national and international consensus guidelines have not recommended the routine use of intra‐cranial imaging to screen for BM in patients with renal cell carcinoma (RCC) in the absence of symptoms. 3 , 4 , 5 The more recent 2022 European Association of Urology Guidelines on Renal Cell Carcinoma similarly do not recommend routine brain imaging for patients with RCC, but suggest offering brain imaging for patients with mRCC. 6 It has been estimated that up to 30% of mRCC patients with BM are asymptomatic.…”

Section: Introductionmentioning

confidence: 99%

Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Brain metastases (BM) in metastatic renal cell carcinoma (mRCC) have been reported to be present in up to 25% of patients diagnosed with mRCC. There is limited published literature evaluating the role of routine intra-cranial imaging for the screening of asymptomatic BM in mRCC.Aims: To evaluate the potential utility of routine intra-cranial imaging, a retrospective cohort study was conducted to characterize the outcomes of mRCC patients who presented with asymptomatic BM, as compared to symptomatic BM. Methods and Results:The Canadian Kidney Cancer Information System (CKCis) database was used to identify mRCC patients diagnosed with BM. This cohort was divided into two groups based on the presence or absence of BM symptoms. Details regarding patient demographics, disease characteristics, systemic treatments, BM characteristics and survival outcomes were extracted. Statistical analysis was through chi-square tests, analysis of variance, and Kaplan-Meier method to characterize survival outcomes. A p-value of <0.05 was considered statistically significant for all

show abstract

“…More recently, targeted agents were replaced as first line treatment by dual checkpoint inhibitor immuno-oncology agents (IO) (6)(7)(8)(9). The role of cytoreductive nephrectomy (CN) in mRCC, previously established in the cytokine era, has been revisited in the targeted therapy era where there may be upfront utility in appropriately selected patients (10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma

Peng

Lalani

Swaminath

2021

CUAJ

View full text Add to dashboard Cite

Introduction: Preclinical evidence demonstrates the immunogenic potential of stereotactic body radiotherapy (SBRT). There is growing interest in investigating this interplay with the immune system in metastatic renal cell carcinoma (mRCC). Cytoreduction with SBRT and combination therapy with SBRT and checkpoint inhibitor immuno-oncology agents (IO) are two potential therapeutic strategies in mRCC. In this review, we summarize the current clinical evidence for the use of cytoreductive SBRT to primary kidney and combination SBRT with IO. Methods: A literature review for articles and abstracts published between January 2000 and March 2020 was conducted through the PubMed, the American Society of Clinical Oncology (ASCO), and the American Society of Radiation Oncology (ASTRO) database. Evaluation of studies followed the Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) criteria. Results: A total of three articles for cytoreductive SBRT and one article and three abstracts for combination SBRT and IO in mRCC met inclusion criteria for this review. Evidence for SBRT to primary kidney is limited by small series and pilot studies. Outcomes vary widely due to small patient numbers and study heterogeneity. Local control ranges from 85–100% and one- and two-year overall survival ranges from 38–71% and 19é53%, respectively. Combination SBRT and IO are tolerable for patients with early data, suggesting grade 3–4 adverse event rates of 0–24%. Long-term survival data is not yet available. Conclusions: Cytoreductive SBRT and combination SBRT with IO therapy represent promising treatment strategies in mRCC. The evidence for clinical benefit is currently limited and requires further study with well-designed, randomized, controlled trials.

show abstract

Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019

Cited by 11 publications

References 84 publications

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021

Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma

Cytoreductive stereotactic body radiotherapy (SBRT) and combination SBRT with immune checkpoint inhibitors (ICIs) in metastatic renal cell carcinoma

Contact Info

Product

Resources

About